This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2005 May 15;11(10):3601-3.

doi: 10.1158/1078-0432.CCR-05-0475.

The pathway to biomarker discovery: carbonic anhydrase IX and the prediction of immune responsiveness

Monica C Panelli¹, Ena Wang, Francesco M Marincola

Affiliations

PMID: 15897553
DOI: 10.1158/1078-0432.CCR-05-0475

Review

The pathway to biomarker discovery: carbonic anhydrase IX and the prediction of immune responsiveness

Monica C Panelli et al. Clin Cancer Res. 2005.

. 2005 May 15;11(10):3601-3.

doi: 10.1158/1078-0432.CCR-05-0475.

Authors

Monica C Panelli¹, Ena Wang, Francesco M Marincola

Affiliation

¹ Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, NIH, Bethesda, Maryland, USA.

PMID: 15897553
DOI: 10.1158/1078-0432.CCR-05-0475

No abstract available

PubMed Disclaimer

Comment on

Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.
Atkins M, Regan M, McDermott D, Mier J, Stanbridge E, Youmans A, Febbo P, Upton M, Lechpammer M, Signoretti S. Atkins M, et al. Clin Cancer Res. 2005 May 15;11(10):3714-21. doi: 10.1158/1078-0432.CCR-04-2019. Clin Cancer Res. 2005. PMID: 15897568

Similar articles

Carbonic anhydrase IX as a predictive biomarker of response to kidney cancer therapy.
Signoretti S, Regan M, Atkins M. Signoretti S, et al. BJU Int. 2008 Jun;101 Suppl 4:31-5. doi: 10.1111/j.1464-410X.2008.07646.x. BJU Int. 2008. PMID: 18430120 Review. No abstract available.
Carbonic anhydrase IX/G250/MN: a molecule too good to be true?
Oosterwijk E. Oosterwijk E. BJU Int. 2008 Mar;101(5):527-8. doi: 10.1111/j.1464-410X.2007.07431.x. BJU Int. 2008. PMID: 18257853 No abstract available.
CA9 gene: single nucleotide polymorphism predicts metastatic renal cell carcinoma prognosis.
de Martino M, Klatte T, Seligson DB, LaRochelle J, Shuch B, Caliliw R, Li Z, Kabbinavar FF, Pantuck AJ, Belldegrun AS. de Martino M, et al. J Urol. 2009 Aug;182(2):728-34. doi: 10.1016/j.juro.2009.03.077. Epub 2009 Jun 18. J Urol. 2009. PMID: 19539328
Carbonic anhydrase IX and renal cell carcinoma: prognosis, response to systemic therapy, and future vaccine strategies.
Shuch B, Li Z, Belldegrun AS. Shuch B, et al. BJU Int. 2008 Jun;101 Suppl 4:25-30. doi: 10.1111/j.1464-410X.2008.07645.x. BJU Int. 2008. PMID: 18430119 Review. No abstract available.
Immunohistochemical expression of carbonic anhydrase IX assessed over time and during treatment in renal cell carcinoma.
Jensen HK, Nordsmark M, Donskov F, Marcussen N, von der Maase H. Jensen HK, et al. BJU Int. 2008 Jun;101 Suppl 4:41-4. doi: 10.1111/j.1464-410X.2008.07649.x. BJU Int. 2008. PMID: 18430123 No abstract available.

See all similar articles

Cited by

Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy.
Sabatino M, Kim-Schulze S, Panelli MC, Stroncek D, Wang E, Taback B, Kim DW, Deraffele G, Pos Z, Marincola FM, Kaufman HL. Sabatino M, et al. J Clin Oncol. 2009 Jun 1;27(16):2645-52. doi: 10.1200/JCO.2008.19.1106. Epub 2009 Apr 13. J Clin Oncol. 2009. PMID: 19364969 Free PMC article. Clinical Trial.
Molecular insights on the peripheral and intratumoral effects of systemic high-dose rIL-2 (aldesleukin) administration for the treatment of metastatic melanoma.
Weiss GR, Grosh WW, Chianese-Bullock KA, Zhao Y, Liu H, Slingluff CL Jr, Marincola FM, Wang E. Weiss GR, et al. Clin Cancer Res. 2011 Dec 1;17(23):7440-50. doi: 10.1158/1078-0432.CCR-11-1650. Epub 2011 Oct 5. Clin Cancer Res. 2011. PMID: 21976537 Free PMC article.
Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology.
Tahara H, Sato M, Thurin M, Wang E, Butterfield LH, Disis ML, Fox BA, Lee PP, Khleif SN, Wigginton JM, Ambs S, Akutsu Y, Chaussabel D, Doki Y, Eremin O, Fridman WH, Hirohashi Y, Imai K, Jacobson J, Jinushi M, Kanamoto A, Kashani-Sabet M, Kato K, Kawakami Y, Kirkwood JM, Kleen TO, Lehmann PV, Liotta L, Lotze MT, Maio M, Malyguine A, Masucci G, Matsubara H, Mayrand-Chung S, Nakamura K, Nishikawa H, Palucka AK, Petricoin EF, Pos Z, Ribas A, Rivoltini L, Sato N, Shiku H, Slingluff CL, Streicher H, Stroncek DF, Takeuchi H, Toyota M, Wada H, Wu X, Wulfkuhle J, Yaguchi T, Zeskind B, Zhao Y, Zocca MB, Marincola FM. Tahara H, et al. J Transl Med. 2009 Jun 17;7:45. doi: 10.1186/1479-5876-7-45. J Transl Med. 2009. PMID: 19534815 Free PMC article.
Carbonic Anhydrase III Promotes Cell Migration and Epithelial-Mesenchymal Transition in Oral Squamous Cell Carcinoma.
Chu YH, Su CW, Hsieh YS, Chen PN, Lin CW, Yang SF. Chu YH, et al. Cells. 2020 Mar 13;9(3):704. doi: 10.3390/cells9030704. Cells. 2020. PMID: 32183030 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Silverchair Information Systems
Medical
- MedlinePlus Health Information